Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.
Growing
The company is in a growing phase, with the latest annual income totaling USD 43.78M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 43.78M.
Overvalued
The company’s latest PE is -0.07, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 876.37K shares, decreasing 70.31% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 14.17K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.85.